CAS: 1070773-09-9

"RK33 is a DDX3 inhibitor causing G1 arrest, apoptosis, and radiation sensitization in DDX3-overexpressing cells."

Applications RK 33 is an inhibitor of DDX3, an ATP-dependent RNA helicase (1). Aberrant regulation of DDX3 is related to various diseases such as prostate and breast cancer (2). RK 33 was shown to decrease proliferation of prostate cancer cells and induced a G1 phase cell-cycle arrest (2). References (1) Botlagunta, M. et al.: PLoS One. 6, e17563 (2011) (2) Xie, M., et al.: Cancer Res. 76, 6340 (2016)

RK33

RK-33 is a small molecule inhibitor, which is synthesized as a chemical compound. It functions by targeting and inhibiting the activity of DDX3, a DEAD-box RNA helicase, which plays a crucial role in the modulation of RNA biogenesis and translation processes. By interfering with DDX3, RK-33 disrupts processes essential for the proliferation of certain cancer cells, making it a significant focus in cancer research. The compound demonstrates potential therapeutic applications in oncology, particularly in the treatment of cancers showing elevated DDX3 activity. Studies have shown its ability to impede the growth of tumor cells in various cancer models, highlighting its role in enhancing the efficacy of existing therapeutic strategies. Researchers are keenly investigating RK-33's effectiveness in combination therapies to better understand its potential in reducing tumor resistance and improving treatment outcomes. Such investigations could pave the way for developing targeted therapies across diverse types of malignancies where DDX3 is a pivotal factor.